Effect of tocilizumab in hospitalized patients with severe pneumonia

COVID-19: a cohort study

- 5 Authors:
- 6 Benjamin Rossi^{1*} and Lee S. Nguyen^{2,3*}, Philippe Zimmermann⁴, Faiza Boucenna¹, Louis
- 7 Dubret⁴, Louise Baucher¹, Helene Guillot¹, Marie-Anne Bouldouyre¹, Yves Allenbach⁵, Joe-
- 8 Elie Salem³, Paul Barsoum⁶, Arezki Oufella⁴ and Helene Gros¹
- 10 * these authors equally contributed to the manuscript
- 11 Affiliation:
- 12 Department of Internal Medicine, Robert Ballanger hospital, 93600 Aulnay-sous-bois,
- 13 France

9

21

25

- ² Research & innovation of CMC Ambroise Paré, 92200 Neuilly-sur-Seine, France
- ³ Sorbonne Université, INSERM, Clinical Investigations Center Paris-Est, CIC-1901, AP.HP.6
- 16 Pitié-Salpétrière, 75013 Paris, France
- ⁴Department of pharmacy, Robert Ballanger hospital, 93600 Aulnay-sous-bois, France
- ⁵ Sorbonne Université, Department of Internal medicine and Clinical Immunology, AP.HP.6
- 19 Pitié-Salpétrière, 75013 Paris, France
- 20 ⁶ Department of cardiology, Robert Ballanger hospital, 93600 Aulnay-sous-bois, France
- 22 Corresponding author
- 23 Dr Benjamin Rossi, Department of internal medicine, 93600 Aulnay-sous-bois, France, tél:
- 24 +33149367021; +33149367199; benjamin.rossi@ght-gpne.fr
- 26 Words: 1872 (2 figures, 1 table)
- 27 **Keywords:** Anti-interleukin-6, COVID-19, SARS CoV2, severe pneumonia, cytokine release
- 28 syndrome
- 30 Abstract (238/250 words)

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

Background. Tocilizumab, a drug targeting interleukin-6 administrated in the right timeframe may be beneficial in coronavirus-disease-2019 (COVID-19). We aimed to assess its benefit, drawing from observations in compassionately treated patients. Methods: In a retrospective case-control study, treatment effect (tocilizumab 400mg, singledose) was assessed using three statistical methods: propensity-score matching, Cox multivariable survival and inverse probability score weighting (IPSW) analyses. Were included all patients hospitalized with COVID-19, who presented severity criteria with SpO2≤96% despite O2-support ≥6L/min for more than 6 hours. Were excluded patients in critical care medicine department and those under invasive mechanical ventilation. Primary outcome was a composite of mortality and ventilation, with a maximum follow-up of 28 days. Results: 246 patients were included (106 treated by tocilizumab). They were 67.6 ±15.3 years-old, with 95 (38.5%) women. Delay between first symptoms and inclusion was 8.4 ±4.5 days. Overall, 105 (42.7%) patients presented the primary outcome, with 71 (28.9%) deaths during the 28-days follow-up. Propensity-score-matched 84 pairs of comparable patients. In the matched cohort (n=168), tocilizumab was associated with fewer primary outcomes (hazard ratio (HR)=0.49 (95% confidence interval (95CI)=0.3-0.81), p-value=0.005). These results were similar in the overall cohort (n=246), with Cox multivariable analysis yielding a protective association between tocilizumab and primary outcome (adjusted HR=0.26 (95CI=0.135-0.51, p=0.0001), confirmed by IPSW analysis (p<0.0001). Analyses on mortality with 28-days follow-up yielded similar results. Conclusion: In this retrospective study, tocilizumab single-dose was associated with improved survival without mechanical ventilation in patients with severe COVID-19. Introduction

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

The pandemic of coronavirus, responsible for the severe acute respiratory syndrome (SARS), called Coronavirus Disease (COVID-19) started in the late 2019. It quickly spread worldwide, notably in Europe.(1) It is responsible for severe pneumonia, resulting in a high rate of transfers to intensive care units (ICU) and in-patients mortality of 5% to 32%.(2) Severity has been related to an exaggerate immune response, the cytokine release syndrome (CRS), mediated by pro inflammatory cytokines, including interleukin IL-6, IL-12 and tumor necrosis factor α leading to various organs dysfunction including lung, brain and heart.(3) Previously, tocilizumab, an antibody targeting IL-6 receptors proved efficient against CRS.(4) Opposing CRS may decrease further inflammatory pulmonary lesions, i.e. respiratory deterioration requiring mechanical ventilation, transfers to ICU and deaths. (5, 6) Starting on March 23, 2020, we administrated off-label tocilizumab in patients with severe COVID-19 pneumonia as compassionate use. In the present report, we assessed the effect of tocilizumab on mortality and mechanical ventilation in a cohort of patients hospitalized for severe COVID-19 pneumonia. To mitigate selection bias, we performed a triple analysis including propensity-score matching, Cox multivariable and inverse probability score weighting analyses, to compare patients who received tocilizumab, to those who did not. Material and method Study population In this observational single-center study, in Robert Ballanger regional hospital, all patients were screened for SARS-coronavirus 2 starting on March 14th, 2020, Diagnosis required positive testing with reverse transcription polymerase chain reaction (RT-PCR) or chest CTscan with typical lesions.(7) Inclusion criteria was severe COVID-19 pneumonia, i.e. pulse

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

oxygen (O2) saturation (SpO2) ≤96% despite O2 flow≥6 L/minute delivered by high concentration oxygen mask, for >6 hours. Were excluded patients under invasive mechanical ventilation and those critical care medicine department. Starting on March 23, 2020, tocilizumab was made available for off-label compassionate use in severe COVID-19 pneumonia in our center. Patients were compared between two group: those who received tocilizumab (a single intravenous injection, 400 mg) and those who did not (control group). This retrospective study was approved by research ethics committee and registered on clinicaltrials.gov (NCT04366206). **Treatment intervention** Tocilizumab was made available for compassionate use by hospital pharmacists on March 23th, 2020. Choice and indication of treatment depended on attending physician, and information was given to all patients prior to being treated. No criteria was retained to exclude patients from treatment, hence patients without full engagement status (i.e. recused from ICU) were still eligible for treatment. Study variables The primary outcome was a composite of all-cause mortality and invasive mechanical ventilation (i.e. requiring tracheal intubation). Follow-up period was 28 days after inclusion. All data were prospectively collected in electronical medical records, which were then extracted for the purpose of this study. List of available data is presented in Supplementary Material. Follow-up was complete for all patients. Statistical analyses Baseline characteristics of patients treated by tocilizumab were compared to that of the control group. In the primary analysis, 1:1 nearest-neighbor propensity-score matching was performed using the following variables: age, sex, smoking status, history of coronary artery

disease, stroke, heart failure or peripheral artery disease, hypertension, chronic kidney disease with eGFR less than 60 mL/min/1m732, cancer, long-term corticosteroid treatment, use of antibiotics, of antivirals, of corticosteroids, of baricitinib after admission, SpO2/FiO2 ratio at admission, time between admission and inclusion, and SpO2/FiO2 ratio and CRP at inclusion.(8) A second analysis using a multivariable Cox proportional hazard analysis was performed in the entire cohort, with the following independent covariables: tocilizumab injection, engagement status, age, systolic blood pressure at inclusion, SpO2/FiO2 ratio at admission and SpO2/FiO2 ratio at inclusion. A third analysis using inverse probability score weighting (IPSW) approach was also performed using the entire cohort.(9) Kaplan-Meier curves were used to compare the two groups in the matched cohort. Cox proportional hazards modeling was used to assess the association between tocilizumab and the primary outcome in the overall cohort. Conclusions were drawn only if the three analyses yielded concordant results. Continuous variables were presented as mean ± standard deviation and categorical variables as number (proportion). All analyses were performed using SPSS (IBM, Armonk, USA) and R software.

· ,

103

104

105

106

107

108

109

110

111

112

113

114

115

116

Results

In total, 106 patients treated by tocilizumab were included and compared to 140 control patients (flow-chart is presented in **Supplementary Material**). Overall, 105 (42.7%) patients presented the primary outcome, with 71 (28.9%) deaths during the 28-days follow-up. Baseline characteristics and comparisons are presented in **Table 1**. In the overall cohort (n=246), patients in the tocilizumab group were younger than those in the control group (64.3 \pm 13.0 vs 70.1 \pm 16.5 years-old, p<0.001), more had full engagement status (73 (68.9%) vs 71 (51.4%), p=0.006), more were treated with antibiotics (106 (100%) vs 134 (95.7%), p=0.04) and by corticosteroids (43 (40.6%) vs 38 (27.1%), p=0.27)(see **Supplementary Table 1** for details on overall cohort). In the tocilizumab group, delay between study inclusion and tocilizumab administration was 1.0 \pm 1.0 days.

Propensity-score matched cohort

Propensity-score matching yielded 84 pairs of patients (for a total of 168 patients in the matched cohort). There was no significant difference between the two matched groups regarding baseline characteristics (see **Table 1**). In the matched cohort (n=168), tocilizumab was associated with fewer events (hazard ratio (HR)=0.49 (95% confidence interval(95%CI)=0.30-0.81), p=0.005)(see **Figure 1**).

Overall cohort (Cox multivariable and IPSW analyses)

In the overall cohort (n=246), Cox multivariable survival analysis found tocilizumab independently associated with a lower incidence of the primary outcome (adjusted HR (adj.HR)=0.34 (95%Cl=0.22-0.52), p<0.0001). Other variables associated with the primary outcome were: SpO2/FiO2 ratio on the day of inclusion (per 1 unit increase, adj.HR=0.987 (95%Cl=0.983-0.991), p<0.0001) and chronic kidney disease (adj.HR=1.63 (95%Cl=1.03-2.52),

p=0.035). IPSW confirmed the protective association between tocilizumab and primary outcome (p<0.0001)(see **Figure 1**).

All-cause mortality (28-days maximum follow-up)

When considering all-cause mortality with a maximum follow-up of 28 days, in the matched cohort (n=168), tocilizumab was associated with fewer deaths (HR=0.42 (95Cl=0.22-0.82), p=0.008). In the overall cohort (n=246), Cox multivariable analysis yielded an independent protective association between tocilizumab and mortality (adj.HR=0.29 (95%Cl=0.17-0.53), p<0.0001), the other independent variables associated with mortality were full engagement status (adj.HR=0.11 (95Cl=0.05-0.23), p<0.0001), S/F ratio at inclusion (per 1-unit increase, adj.HR=0.99 (95Cl=0.985-0.995), p<0.0001), chronic kidney disease (adj.HR=2.0 (95Cl=1.22-3.27), p=0.006) and systolic blood pressure at inclusion (per 1-mmHg increase, adj.HR=1.016 (95Cl=1.005-1.028), p=0.006). IPSW analysis was concordant (p<0.0001)(see Figure 2).

Sensitivity analyses

As sensitivity analysis, we focused on the subgroup of patients with full engagement status: 155 patients, including 73 (50.3%) treated with tocilizumab. In these 155 patients, 33 patients presented the primary outcome. Cox multivariable analyses yielded a protective association between tocilizumab and the primary outcome (adj.HR=0.43 (95Cl=0.22-0.81) p=0.01); the other variables independently associated with the primary outcome were SpO2/FiO2 ratio at inclusion (per 1-unit increase, adj.HR=0.985 (95Cl=0.979-0.992) p<0.0001) and temperature at inclusion (per 1°C-increase, adj.HR=1.39 (95Cl=1.088-1.771), p=0.008). Similarly, in these 155 patients, 9 died during 28-days follow-up. Cox multivariable

analyses yielded a protective association between tocilizumab and the mortality (adj.HR=0.11 (95Cl=0.01-0.89) p=0.039).

In a second sensitivity analysis, we excluded patients who presented an outcome during the first 48 hours, to mitigate selection bias (including immortal time bias). This dataset comprised 204 patients, with 97 treated by tocilizumab; 63 patients presented the primary outcome, and 46 died during 28-days follow-up. Using triple statistical method as in the main analysis, tocilizumab was found significantly associated with fewer primary outcomes (Cox multivariable analysis yielded adj.HR=0.40 (95Cl=0.23-0.70), p=0.001)(see Supplementary Figure 1). Similarly, tocilizumab was found protectively associated with mortality (adj.HR=0.36 (95Cl=0.18-0.70) p=0.003)(see Supplementary Figure 2)(details of all multivariable models are presented in Supplementary Material).

Discussion

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

In this single-center retrospective study in 246 patients, with 106 treated by tocilizumab, we observed a significant association between tocilizumab and fewer deaths and requirement for invasive mechanical ventilation; in patients hospitalized for severe COVID-19 pneumonia, with 28-days follow-up. The study cohort was similar to that of previously described COVID-19 patients with a median age of 68 years, 27.6% presenting cardiovascular history and 30.1% were obese.(10) Median delay between first symptoms and treatment was 8 days, corresponding to the delay of CRS onset described in SARS-Cov-2.(11) Attenuating CRS may partly explain the significant decrease in the primary outcome.(5, 6) CRS was related to interleukin accumulation, and a recent trial studying effect of interleukin-1 blockade found significant improvement.(12) Similarly, in our study, clinical improvement observed in patients treated by tocilizumab was akin to that described in a single-center observational study in which 100 patients with Covid-19 were treated with tocilizumab. With 20/100, 17.5% patients who died by day 10, these results are akin to ours (with 28.9% deaths by day 28).(13) Interestingly, in that study, tocilizumab administration protocol mentioned 800 mg twice in 87 patients and 800 mg three times in 13 patients, similar to that of ongoing trials with two injections of up to 800 mg each, within a 3-days period.(14, 15) In comparison, in our study, dosage of tocilizumab was 400 mg, injected once, following previous reports of improved outcomes chimeric antigen receptor-T-cell-induced CRS with 8 mg/kg dosage.(4) Further confirming our results with the same dosage would

improve the availability of this costly biotherapy for which access may become an issue. (16)

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

We acknowledge several limitations. First, the single-center nature of this study requires external validation, however, it guarantees homogeneity in the care of all patients, in our non-ICU departments dedicated to treat COVID-19 patients, i.e. observed differences are more likely to be due to tocilizumab. Second, although we aimed to mitigate selection bias using three statistical methods, including propensity-score matching, Cox multivariable and IPSW analyses, residual confounders are plausible. (8, 9) Due to comorbidities and lack of beds in the context of Covid-19 pandemic, a significant proportion of patients were labeled as limited, regarding possibilities of being transferred in critical care medicine department, as well as invasive mechanical ventilation. However, these criteria did not alter indications for tocilizumab, as a third was considered limited at admission. All analyses were adjusted for this criterion in multivariable models. Furthermore, we performed additional sensitivity analyses to further mitigate selection bias; analyses which yielded similar results with significant association between tocilizumab and better survival without mechanical ventilation, even focusing on patients with full therapeutic engagement (n=155). Third, because arterial partial pressure of O2 was not available in all patients, we used SpO2/Fio2 ratio to assess respiratory dysfunction, a validated marker in acute lung injury.(17) Fourth, use of non-invasive ventilation and high-flow oxygenotherapy changed during the study period, following evolving guidelines which advocated against during the first weeks of pandemic to decrease virus aerosol propagation, and were then made more flexible. The relative low proportion of patients who benefited from these treatments and the fact that there was no difference between the two groups regarding this criterion decreases chances of it being a bias although, residual confounding biases may remain. Finally, we did not systematically assay IL-6, which may have proven valuable to identify patients for whom effect was greater.(6)

These results point towards a clinical benefit of tocilizumab, however, they may not replace a full-fledged randomized controlled trial, focusing on dosage adjustment and on patients managed early, so that CRS may be adequately attenuated in patients with Covid-19 evolving towards clinical deterioration.

Conclusion

In this observational single-center study, in hospitalized patients presenting with severe COVID-19 pneumonia, tocilizumab 400 mg single-dose was associated with lower mortality and need for mechanical ventilation. These results warrant further clinical trials for confirmation and dosage validation.

Table 1. Baseline characteristics, at admission and at inclusion.

	Control (n=140)	Tocilizumab (n=106)	p-value	Matched control (n=84)	Matched tocilizumab (n=84)	p-value
Clinical features, No (%)						
Age, mean±SD, years	70.1 ±16.5	64.3 ±13.0	0.003	64.4 ±16.9	64.8 ±12.8	0.88
Female	59 (42.1%)	36 (34.0%)	0.19	35 (41.7%)	29 (34.5%)	0.24
Full engagement	72 (51.4%)	73 (68.9%)	0.006	56 (66.7%)	58 (69%)	0.74
Diabetes	53 (37.9%)	48 (45.3%)	0.24	31 (36.9%)	35 (41.7%)	0.53 [†]
Insulin treatment	23 (16.4%)	17 (16.0%)	0.93	12 (14.3%)	9 (10.7%)	0.48
Obesity (BMI>30kg/m ²)	40 (28.6%)	34 (32.1%)	0.55	26 (31.0%)	27 (32.1%)	0.87
Hypertension	79 (56.4%)	64 (60.4%)	0.53	47 (56.0%)	47 (56.0%)	1
ACEI treatment	21 (15.0%)	16 (15.1%)	0.98	11 (13.1%)	12 (14.3%)	0.82
ARB treatment	22 (15.7%)	28 (26.4%)	0.039	14 (16.7%)	20 (23.8%)	0.25
History of cardiovascular disease, stroke,	43 (30.7%)	25 (23.6%)	0.22	21 (25.0%)	21 (25.0%)	0.1
peripheral artery disease, heart failure						
Smoker (active or past)	29 (20.7%)	33 (31.1%)	0.06	21 (25.0%)	23 (27.4%)	0.73 [†]
History of COPD, asthma, emphysema,			0.369 [†]			0.53 [†]
fibrosis	22 (15.7%)	17 (16.0%)		12 (14.3%)	15 (17.9%)	
eGFR<60 ml/min/1,73m ²	24 (17.1%)	17 (16.0%)	0.82	13 (15.5%)	12 (14.3%)	0.83
Solid organ transplantation	3 (2.1%)	0 (0.0%)	0.26	2 (2.4%)	0 (0.0%)	0.5
HIV	1 (0.7%)	1 (0.9%)	1‡	1 (1.2%)	0 (0.0%)	1‡
mmunosuppressant drugs	12 (8.6%)	5 (4.7%)	0.24	4 (4.8%)	4 (4.8%)	1‡
Long-term oral corticosteroids	13 (9,3%)	5 (4,7%)	0.17	6 (7.1%)	4 (4.8%)	0.75
Malignancy (active)	17 (12.1%)	6 (5.7%)	0.08	7 (8.3%)	5 (6.0%)	0.55
Treatments after admission	-			-1		
No.(%) under antibiotics	134 (95.7%)	106 (100.0%)	0.04	84 (100.0%)	84 (100.0%)	NA
Betalactamin	129 (92.1%)	105 (99.1%)	0.13 [‡]	81 (96.4%)	83 (98.8%)	0.62 [‡]
Macrolide	98 (70.0%)	93 (87.7%)	0.001	64 (76.2%)	75 (89.3%)	0.025
Others	21 (15.0%)	7 (6.6%)	0.04	15 (17.9%)	6 (7.1%)	0.036
No. (%) under antiviral therapy	106 (75.7%)	88 (83.0%)	0.16	68 (81.0%)	68 (81.0%)	1
Hydroxychloroquine	100 (71.4%)	88 (83.0%)	0.034	62 (73.8%)	68 (81.0%)	0.27
Lopinavir/ritonavir	8 (5.7%)	1 (0.9%)	0.08	8 (9.5%)	1 (1.2%)	0.03
mmun osuppressants and/or	47 (33.6%)	43 (40.6%)	0.26	24 (28.6%)	26 (31.0%)	0.74
corticosteroids	, ,	, ,		, ,	, ,	
Baricitinib	18 (12.9%)	1 (0.9%)	0.001	0 (0.0%)	1 (1.2%)	1 *
Characteristics at hospital admission	, ,	, ,		, ,	, ,	
Delay bet ween first symptoms and			0.74*			0.29*
admission, means±SD, days	5.4 ±8.8	4.8 ±15.3		5.2 ±9.8	6.5 ±4.9	
SpO2/FiO2 ratio, mean ±SD	327.4 ±108.7	338.4 ±88.6	0.39*	330.3 ±108.6	341.8 ±87.1	0.45*
SpO2, mean ±SD, %	93.9 ±3.6	94.0 ±3.9	0.81*	94.0 ±3.6	94.2 ±3.3	0.62
Oxygen flow, mean ±SD, L/min	4.0 ±4.8	3.1 ±3.6	0.44	3.9 ±4.6	3.0 ±3.3	0.54
PaO2, mean ±SD, mmHg	70.4 ±24.7	68.6 ±17.5	0.54*	71.6 ±28.4	68.6 ±17.8	0.46
Temperature, mean +SD, °C	37.2 ±1.1	37.5 ±1.2	0.06*	37.3 ±1.1	37.5 ±1.2	0.22

C-reactive protein, mean \pm SD, mg/L	132.1 ±99.2	135.2 ±88.2	0.79*	138.2 ±101.7	131.5 ±84.6	0.64*
Lymphocyte count, mean ±SD, mcL	1451.9 ±3320.1	1198.6 ±1095.7	0.40*	1595.9 ±4290.1	1228, 7 ±1204.0	0.46*
Characteristics at study inclusion						
Delay between first symptoms and	8.4 ±4.7	8.3 ±4.2	0.82*	8.4 ±4,8	8.6 ±4.2	0.84*
inclusion, mean ±SD, days						
Delay between admission and inclusion,	3.0 ±8.0	3.5 ±14.6	0.28	3.2 ±8.5	2,2 ±3.3	0.61
mean ±SD, days						
SpO2/FiO2 ratio, mean \pm SD,	212.9 ±41.7	199.4 ±49.8	0.02	210.9 ±41.9	206.5 ±48.7	0.53*
SpO2, mean ±SD, %	94.5 ±3.6	94.0 ±3.7	0.32*	94.3 ±4.0	94.2 ±3.6	0.84*
O2 flow support, mean ±SD, I/min	8.4 ±3.4	9.9 ±5.3	0.03	8.6 ±3.4	9,3 ±4.8	
						0.59 [§]
PaO2, mean ±SD, mmHg	74.3 ±25.4	76.8 ±24.5	0.51	75.7 ±29.0	78.3 ±24.8	0.59*
PaCO2, mean ±SD, mmHg	36.0 ±9.1	35.9 ±7.7	0.93*	36.3 ±9.0	35.6 ±7.6	0.63*
Systolic blood pressure, mean \pm SD, mmHg	130.7 ±20.0	131.4 ±20.9	0.8*	131.3 ±21.2	130.8 ±20.3	0.9*
Temperature, mean ±SD, °C	37.3 ±1.2	37.3 ±1.2	0.61	37.3 ±1.3	37.3 ±1.1	0.55
C-reactive protein, mean ±SD, mg/L	144.9 ±100.7	168.0 ±95.0	0.07*	150.8 ±105.1	163.7 ±97.9	0.42*
Lymphocyte count, mean ±SD, mcL	1224.0 ±2294.0	1128.4 ±1010.8	0.66	1278.8 ±2907.4	1168.8 ±1108.5	0.75 [§]
eGFR, mean \pm SD, ml/min/1,73m ²	72.6 ±34.7	152.2 ±701.9	0.25*	75.2 ±34.5	171.8 ±788.2	0.27*
Use non-invasive ventilation or high flow	5 (3.6%)	8 (7.5%)	0.17	4 (4.8%)	4 (4.8%)	1.0
oxygenotherapy after inclusion						

Data are presented as number (percentage), unless otherwise noted. Comparison methods were noted: * for Student; † for Chi-2; ‡ for Fischer and § for Mann-Whitney test. Significant intergroup differences are in bold.

Abbreviations: O2: oxygen; ACEI: angiotensin conversion enzyme inhibitor; ARB: angiotensin II receptor blocker; BMI: body-mass index; eGFR: estimated glomerular filtration rate by modification of diet in renal disease (MDRD) formula; FiO2: fraction of inspired oxygen; HIV: human immunodeficiency virus; IQR: interquartile range; SpO2: pulse oximetry O2 saturation

Figure 1. Survival curves, regarding the primary outcome with a 28-days follow-up, comparing tocilizumab and control group.

In the matched cohort (n=168), tocilizumab was associated with fewer events (hazard ratio (HR)=0.49 (95% confidence interval(95%CI)=0.30-0.81), p=0.005). In the overall cohort (n=246), Cox multivariable survival analysis found tocilizumab independently associated with a lower incidence of the primary outcome (adjusted HR =0.34 (95%CI=0.22-0.52), p<0.0001). Inverse probability score-weighted analysis yielded similar results (p<0.0001).

tocilizumab and control group.

In the matched cohort (n=168), tocilizumab was associated with fewer deaths (hazard ratio=0.42 (95Cl=0.22-0.82), p=0.008). In the overall cohort (n=246), Cox multivariable analysis yielded an independent protective association between tocilizumab and mortality (adjusted HR=0.29 (95%Cl=0.17-0.53), p<0.0001). Inverse probability score-weighted analysis yielded similar results (p<0.0001).

REFERENCES

261

272

273

274

275

276

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

299

300

301

- 1. Spiteri G, Fielding J, Diercke M, Campese C, Enouf V, Gaymard A, Bella A, Sognamiglio P, 262 263 Sierra Moros MJ, Riutort AN, Demina YV, Mahieu R, Broas M, Bengnér M, Buda S, 264 Schilling J, Filleul L, Lepoutre A, Saura C, Mailles A, Levy-Bruhl D, Coignard B, Bernard-265 Stoecklin S, Behillil S, van der Werf S, Valette M, Lina B, Riccardo F, Nicastri E, Casas I, 266 Larrauri A, Salom Castell M, Pozo F, Maksyutov RA, Martin C, Van Ranst M, Bossuyt 267 N, Siira L, Sane J, Tegmark-Wisell K, Palmérus M, Broberg EK, Beauté J, Jorgensen P, 268 Bundle N, Pereyaslov D, Adlhoch C, Pukkila J, Pebody R, Olsen S, Ciancio BC. First 269 cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 270 January to 21 February 2020. Euro surveillance: bulletin Europeen sur les maladies 271 transmissibles = European communicable disease bulletin 2020; 25.
 - 2. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, Pesenti A. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *Jama* 2020.
- 3. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider
 cytokine storm syndromes and immunosuppression. *Lancet (London, England)* 2020;
 395: 1033-1034.
 - 4. Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, Przepiorka D, Farrell AT, Pazdur R. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. *The oncologist* 2018; 23: 943-947.
 - 5. Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? *Journal of autoimmunity* 2020: 102452.
 - 6. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. *International journal of antimicrobial agents* 2020: 105954.
 - 7. Rubin GD, Ryerson CJ, Haramati LB, Sverzellati N, Kanne JP, Raoof S, Schluger NW, Volpi A, Yim JJ, Martin IBK, Anderson DJ, Kong C, Altes T, Bush A, Desai SR, Goldin J, Goo JM, Humbert M, Inoue Y, Kauczor HU, Luo F, Mazzone PJ, Prokop M, Remy-Jardin M, Richeldi L, Schaefer-Prokop CM, Tomiyama N, Wells AU, Leung AN. The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. *Chest* 2020.
- 296 8. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in 297 estimation of causal treatment effects: a comparative study. *Statistics in medicine* 298 2004; 23: 2937-2960.
 - 9. Austin PC, Stuart EA. The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes. Statistical methods in medical research 2017; 26: 1654-1670.
- 10. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, Barnaby
 DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA,
 Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA,
 Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting

- Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *Jama* 2020.
- 11. Han Y, Liu Y, Zhou L, Chen E, Liu P, Pan X, Lu Y. Epidemiological Assessment of Imported
 Coronavirus Disease 2019 (COVID-19) Cases in the Most Affected City Outside of
 Hubei Province, Wenzhou, China. JAMA Network Open 2020; 3: e206785-e206785.
- 12. Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, Sacco E, Naccache J-M, Bézie Y, Laplanche S, Le Berre A, Le Pavec J, Salmeron S, Emmerich J, Mourad J-J,
 Chatellier G, Hayem G. Anakinra for severe forms of COVID-19: a cohort study. *The Lancet Rheumatology*.
- 316 13. Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, Franceschini F, Airò P, Bazzani 317 C, Beindorf EA, Berlendis M, Bezzi M, Bossini N, Castellano M, Cattaneo S, Cavazzana 318 I, Contessi GB, Crippa M, Delbarba A, De Peri E, Faletti A, Filippini M, Filippini M, 319 Frassi M, Gaggiotti M, Gorla R, Lanspa M, Lorenzotti S, Marino R, Maroldi R, Metra M, 320 Matteelli A, Modina D, Moioli G, Montani G, Muiesan ML, Odolini S, Peli E, Pesenti S, 321 Pezzoli MC, Pirola I, Pozzi A, Proto A, Rasulo FA, Renisi G, Ricci C, Rizzoni D, Romanelli 322 G, Rossi M, Salvetti M, Scolari F, Signorini L, Taglietti M, Tomasoni G, Tomasoni LR, 323 Turla F, Valsecchi A, Zani D, Zuccalà F, Zunica F, Focà E, Andreoli L, Latronico N. Tocilizumab for the treatment of severe COVID-19 pneumonia with 324 325 hyperinflammatory syndrome and acute respiratory failure: A single center study of 326 100 patients in Brescia, Italy. Autoimmunity reviews 2020: 102568.
- 327 14. CORIMUNO-19 Tocilizumab trial TOCI (CORIMUNO-TOCI). 2020.

- 15. A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA). 2020.
- 16. Chiu Y, Ostor AJ, Hammond A, Sokoll K, Anderson M, Buch M, Ehrenstein MR, Gordon P,
 Steer S, Bruce IN. Access to the next wave of biologic therapies (Abatacept and
 Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales:
 addressing treatment outside the current NICE guidance. Clinical rheumatology 2012;
 31: 1005-1012.
- 335 17. Bilan N, Dastranji A, Ghalehgolab Behbahani A. Comparison of the spo2/fio2 ratio and the pao2/fio2 ratio in patients with acute lung injury or acute respiratory distress syndrome. *Journal of cardiovascular and thoracic research* 2015; 7: 28-31.



